Modulation of cb1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the chinese hamster ovary cell expression system

Journal of Pharmacology and Experimental Therapeutics

Volumn 287, Issue 3, 1998, Pages 1038-1047

  Rinaldi Carmona, Murielle ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID; CANNABINOID RECEPTOR; CYCLIC AMP; CYCLOHEXANOL DERIVATIVE; DRUG RECEPTOR; PIPERIDINE DERIVATIVE; PROTEIN KINASE (CALCIUM,CALMODULIN); PYRAZOLE DERIVATIVE; RIMONABANT; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL MEMBRANE; CHO CELL; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSFECTION; HAMSTER; HUMAN; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; ANIMAL CELL; CONFOCAL MICROSCOPY; FLUORESCENCE ACTIVATED CELL SORTER; GENE EXPRESSION REGULATION; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SECOND MESSENGER;

ANIMALS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CANNABINOIDS; CELL MEMBRANE; CHO CELLS; CRICETINAE; CYCLIC AMP; CYCLOHEXANOLS; HUMANS; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 0032239756     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Andersen NG, Maller JL, Tonks NK and Sturgill TW (1990) Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 343:651-653.
2. Attramadal H, Arizza JL, Aoki C, Dawson TM, Codina J, Kwatra M, Snyder SH, Caron MG and Lefkowitz RJ (1992) Beta arrestin 2 a novel member of the arrestin-beta-arrestin gene family. J Biol Chem 267:17882-17890.
3. Barker EL and Sanders-Bush E (1993) 5-hydroxytryptamine-lC receptor density and mRNA levels in choroid plexus epithelial cells after treatment with mianserin and (-)-l-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. Mol Pharmacol 44: 725-730.
4. Barker EL, Westphal RS, Schmidt D and Sanders-Bush E (1994) Constitutively active 5-hydroxytryptamine 2C (5HT2C) receptors reveal novel inverse agonist activity of receptor ligands. J Biol Chem 269:11687-11690.
5. Benovic JL, Onorato J, Lohse MJ, Dohlman HG, Staniszewski C, Caron MG and Lefkowitz RJ (1990) Synthetic peptides of the hamster β2-adrenoceptor as substrates and inhibitors of the -adrenoceptor kinase. Br J Pharmacol 30:3S-12S.
6. Blaukat A, Abd Alia S, Lohae MJ and Müller-Esterl W (1996) Ligand-induced phosphorylation/dephosphorylation of the endogenous bradykinin 2 receptor from human fibroblasts. J Biol Chem 271:32366-32374.
7. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G and Casellas P (1993) Cannabinoid-receptor expression in human leucocytes. Ear J Biol Chem 214:173-180.
8. Bouaboula M, Poinot-Chazel C, Bourrié B, Calandra B, Rinaldi-Carmona M, Le Fur G and Casellas P (1995a) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312:637-641.
9. Bouaboula M, Bourrié B, Rinaldi-Carmona M, Shire D, Le Fur G and Casellas P (1995b) Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. J Biol Chem 270:13973-13980.
10. Bouaboula M, Poinot-Chazel C, Marchand J, Canat X, Bourrië B, Rinaldi-Carmona M, Calandra B, Le Fur G and Casellas P (1996) Signalling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinases and induction of Krox-24 expression. Eur J Biochem 237:704-711.
11. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Earth F, Calandra B, Pecceu F, Lupker J, Maffrand J-P, Le Fur G and Casellas P (1997) SR 141716A, a selective inverse agonist for central cannabinoid receptor, inhibits MAPK activation stimulated by insulin or IGF1. Evidence for receptor/ ligand interactions. J Biol Chem 272:22330-22339.
12. Chun M, Liyanage U, Lisanti M and Lodish H (1994) Signal transduction of a protein-coupled receptor in caveolae: colocalization of endothelin and its receptor with caveolin. Proc Nail Acad Sci USA 91:11728-11732.
13. Creese I and Sibley D (1981) Receptor adaptations to centrally acting drugs. Anna Rev Pharm Tax 21:357-391.
14. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
15. Derocq JM, Ségui M, Marchand J, Le Fur G and Casellas P (1995) Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEES Lett 369: 177-182.
16. Mac Ewan DJ and Milligan G (1996) Inverse agonist-induced up-regulation of the human 2-adrenoreceptor in transfected neuroblastoma X glioma hybrid cells. Mol Pharmacol 50:1479-1486.
17. Fan F, Compton DR, Ward S, Melvin L and Martin BR (1994) Development of cross-tolerance between A9-THC, CP 55,940 and WIN 55,212-2. J Pharmacol Exp Ter 271:1383-1390.
18. Fan F, Tao Q, Abood M and Martin BR (1996) Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. Brain Res 706:13-23.
19. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, Lai Y, Ma A and Mitchell RL (1995) Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48:443-450.
20. Fride E (1995) Anandamide: tolerance and cross-tolerance to A9-tetrahydrocannabinol. Brain Res 697:83-90.
21. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G and Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human tissues and leucocytes subpopulations. Eur J Biochem 232:54-61.
22. Gérard CM, Mollereau C, Vassart G and Parmentier M (1991) Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279: 129-134.
23. Grady EF, Garland AG, Gamp PD, Lovett M, Payan DG and Bunnett NW (1995I Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor. Mol Biol Cell 6:509-524.
24. Grady EF, Slice LW, Brant WO, Walsh JH and Bunnett NW (1995) Direct observation of endocytosis of gastrin releasing peptide and its receptor. J Biol Chem 270:4603-4611.
25. Graham FL and Van der Eb AJ (1973) Transformation of rat cells by DNA of human adenovirus 5. Virology 54:536-539.
26. Hewlett AC and Fleming RM (1984) Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 26:532-538.
27. Kaminski NE, Abood M, Kessler FK, Martin BR and Schatz AR (1992) Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol 42:736742.
28. Kenakin T (1996) The classification of seven transmembrane receptors in recombinant expressions systems. Pharmacol Rev 48:413-463.
29. Koenig JA and Edwardson JM (1994) Kinetic analysis of the trafficking of muscarinic acetylcholine receptors between the plasma membrane and intracellular compartments. J Biol Chem 269:17174-17182.
30. Labrecque J, Fargin A, Bouvier M, Chidiac P and Dennis M (1995) Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells. Mol Pharmacol 48:150-159.
31. Landsman R, Burkey T, Consroe P, Roeske W and Yamamura H (1997) SR 141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 334.-R1-R2.
32. Lefkowitz RJ, Cotecchia S and Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. TIPS 14:304-307.
33. Lohse MJ, Benovic JL, Codina J, Caron MG and Lefkowitz RJ (1990) Beta arrestin a protein that regulates beta-adrenergic receptor function. Science 248:1547-1550.
34. Mackie K and Hille B (1992) Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Null Acad Sci USA 89:3825-3829.
35. Massi P, Patrini G, Rubino T, Fuzio D and Parolaro D (1997) Changes in rat spleen cannabinoid receptors after chronic CP 55,940: An autoradiographic study. Pharmacol Biochem Behav 58:73-78.
36. Matsuda LA, Lolait SJ, Brownstein BJ, Young AC and Bonner TL (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
37. Milligan G, Bond RA and Lee M (1995) Inverse agonism: pharmacological curiosity or potential therapeutic strategy. Trends Pharmacol Sci 16:10-13.
38. Miloux B and Lupker JH (1994) Rapid isolation of highly productive recombinant Chinese Hamster Ovary cell lines. Gene 149:341-344.
39. Munro S, Thomas KL and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65.
40. Onorato JJ, Palczewski K, Regan JW, Caron MG, Lefkowitz RJ and Benovic JL (1991) Role of acidic amino acids in peptide substrates of the beta adrenergic receptor kinase and rhodopsin kinase. Biochemistry 30:5118-5125.
41. Oviedo A, Glowa J and Herkenham M (1993) Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: A autoradiographic study. Brain Res 616:293-302.
42. Ozcelebi F, Rao RV, Holicky E, Madden BJ, McCornick DJ and Miller LJ (1996) Phosphorylation of cholecystokinin receptors expressed on Chinese hamster ovary cells. Similarities and differences relative to native pancreaticacinar cell receptors. JEM Chem 271:3750-3755.
43. Pak Y, Kouvelas A, Scheideler MA, Rasmussen J, O'Dowd BF and George SR (19961 Agonist-induced functional desensitization of the jx-opioid receptor is mediated by loss of receptors rather than uncoupling from G protein. Moi Pharmacol 50:12141222.
44. Palczewski K, Arendt A, McDowell JH and Margrave PA (1989) Substrate recognition determinants for rhodopsin kinase studies with synthetic peptides polyanions and polycations. Biochemistry 28:8764-8770.
45. Pertwee RG (1991) Tolerance and dependence on psychotropic cannabinoids, in The Biological Banes of Drug Tolerance and Dependence (Pratt JA ed) pp 231-263, Academic Press, New York.
46. Pertwee RG, Stevenson L and Griffin G (1993) Cross-tolerance between delta-9tetrahydrocannabinol and the cannabimimetic agents CP 55,940, WIN 55,212-2 and anandamide. Br J Pharmacol 110:1483-1490.
47. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Brelière JC and Le Fur G (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEES Lett 350:240-244.
48. Rinaldi-Carmona M, Barth F, Héaulme M, Alonso R, Shire D, Congy C, Soubrié P, Brelière JC and Le Fur G (1995) Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56:1941-1947.
49. Rinaldi-Carmona M, Calandra B, Shire D, Bouaboula M, Oustric D, Barth F, Caselias P, Ferrara P and Le Fur G (1996) Characterization of two cloned human CB1 cannabinoid receptor isoforms. J Pharmacol Exp Ther 278:871-878.
50. Rodriguez De Fonseca F, Gorriti MA, Fernandez-Ruiz JJ, Palomo T and Ramos JA (1994) Down-regulation of rat brain cannabinoid binding sites after chronic A9tetrahydrocannabinol treatment. Pharmacol Biochem Behau 47:33-40.
51. Rubino T, Massi P, Patrini G, Venier I, Giagnoni G and Parolaro D (1994) Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybrid ization study. NeuroReport 5:2493-2496.
52. Scarpace PJ and Abrass IB (1982) Desensitization of adenylate cyclase and downregulation of beta-adrenergic receptors after in vivo administration of beta agonist. J Pharmacol Exp Ther 223:327-331.
53. Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, Le Fur G, Caput D and Ferrara P (1995) An amino terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 270:3726-3731.
54. Shire D, Calandra B, Delpech M, Dumont X, Kaghad M, Le Fur G, Caput D and Ferrara P (1996) Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J Biol Chem 271:6941-6946.
55. Slipetz D, O'Neill G, Favreau L, Dufresne C, Gallant M, Gareau Y, Guay D, Labelle M and Metters C (1995) Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 48:352-361.
56. Thomas RF, Holt BD, Schwinn DA and Liggett SB (1992) Long-term agonist exposure induces up-regulation of 3-adrenergic receptor expression via multiple cAMP response elements. Proc Natl Acad Sci USA 89:4490-4494.
57. Tietz E, Rosenberg H and Chiu T (1986) Autoradiographic localization of benzodiazepine receptor down-regulation. J Pharmacol Exp Ther 236:282-292.
58. Twitchell W, Brown S and Mackie K (1997) Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 78:43-50.
59. Von Zastrow M and Krobilka BK (1992) Ligand-regulated internalization and recycling of human 2-adrenergic receptors between the plasma membrane and endosomes containing transferrin receptors. J Biol Chem 267:3530-3538.
60. Werling L, McMahon P and Cox B (1989) Selective changes in mu-opioid receptor properties induced by chronic morphine exposure. Proc Natl Acad Sci USA 86: 6393-6397.
61. Westlake TM, Howlett AC, Bonner TI, Matsuda LA and Herkenham M (1994) Cannabinoid receptor binding and messenger RNA expression in human brain. An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neurosciences 63:637-652.